Drugs · acquisition-cost intelligence
Rasuvo
methotrexate· ingredient methotrexateOther immunosuppressants· METHOTREXATE SODIUM 10 mg/.2mL; METHOTREXATE SODIUM 12.5 mg/.25mL; METHOTREXATE SODIUM 15 mg/.3mL; METHOTREXATE SODIUM 17.5 mg/.35mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$482.29
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-04-012026-04-01
Same-ingredient options by acquisition cost
Other methotrexate products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Methotrexate | $0.16406 | −$482.13 |
| Methotrexate | $1.23 | −$481.06 |
| methotrexate | $2.57 | −$479.72 |
| Methotrexate | $3.36 | −$478.93 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.